Formulation And Evaluation of Anti-Inflammatory Gel from Momordica Charantia Leaves

Momordica charantia, commonly known as bitter gourd, is a widely recognized medicinal plant used traditionally to treat various ailments, including inflammatory conditions. The leaves of M. charantia are particularly rich in bioactive compounds such as saponins, flavonoids, and alkaloids, which exhibit potent anti-inflammatory properties. This review aims to provide a comprehensive overview of the formulation and evaluation of an anti-inflammatory gel derived from M. charantia leaves, examining its potential therapeutic applications.The review begins with an exploration of the phytochemical profile of M. charantia leaves, emphasizing the significance of the identified compounds in mitigating inflammation. Saponins and flavonoids are highlighted for their ability to modulate inflammatory pathways, while alkaloids contribute to analgesic effects. Understanding these compounds is crucial for formulating an effective gel. In discussing the formulation process, the review details the selection of appropriate gel bases, including carbomers, xanthan gum, and sodium alginate, focusing on their rheological properties and compatibility with skin. Extraction methods, such as cold extraction and Soxhlet extraction, are analyzed for their efficiency in preserving the bioactivity of the leaf extracts. The incorporation of extracts into gel bases is outlined, ensuring uniform distribution for optimal therapeutic outcomes.The evaluation of the anti-inflammatory gel encompasses several key aspects. Physicochemical properties, such as pH, viscosity, and stability, are assessed to ensure formulation integrity. In vitro studies, including albumin denaturation and membrane stabilization assays, are employed to evaluate anti-inflammatory efficacy, while cytotoxicity assays determine the safety profile of the gel. Furthermore, in vivo studies utilizing animal models provide insights into the gel’s effectiveness in reducing inflammation and assessing potential side effects. Clinical trials are essential for confirming the gel’s efficacy and safety in human subjects, paving the way for its integration into modern therapeutic practices. This review underscores the potential of M. charantia leaves as a source of natural anti-inflammatory agents and highlights the importance of rigorous scientific evaluation in developing effective topical treatments. In conclusion, the formulation of an anti-inflammatory gel from M. charantia leaves represents a promising area of research, bridging traditional knowledge with contemporary pharmaceutical practices. This review serves as a foundation for future studies aimed at optimizing the gel formulation and exploring the therapeutic applications of M. charantia in treating inflammatory conditions, ultimately contributing to the development of safe, effective, and natural healthcare solutions.